Introduction
The global burden of tuberculosis (TB) is currently still very high. It represents one of the major causes of infectious disease mortality despite the availability of curative treatmen. 1 Moreover, latent tuberculosis infection (LTBI) affects over a third of the worldwide population posing a high risk for later reactivation of the disease. Therefore, TB chemotherapy is essential as an intention-to-cure measure and also as a public health policy to prevent Mycobacterium tuberculosis transmission.